Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial
Anita Boyapati, Matthew F Wipperman, Peter J Ehmann, Sara Hamon, David J Lederer, Alpana Waldron, John J Flanagan, Elif Karayusuf, Rafia Bhore, Michael C Nivens, Jennifer D Hamilton, Giane Sumner, Sumathi Sivapalasingam, Anita Boyapati, Matthew F Wipperman, Peter J Ehmann, Sara Hamon, David J Lederer, Alpana Waldron, John J Flanagan, Elif Karayusuf, Rafia Bhore, Michael C Nivens, Jennifer D Hamilton, Giane Sumner, Sumathi Sivapalasingam
Abstract
Background: Elucidating the relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load and clinical outcomes is critical for understanding coronavirus disease 2019 (COVID-19).
Methods: The SARS-CoV-2 levels were analyzed by quantitative real-time polymerase chain reaction (RT-qPCR) of nasopharyngeal or oropharyngeal swab specimens collected at baseline, and clinical outcomes were recorded over 60 days from 1362 COVID-19 hospitalized patients enrolled in a multicenter, randomized, placebo-controlled phase 2/3 trial of sarilumab for COVID-19 (ClinicalTrials.gov NCT04315298).
Results: In post hoc analyses, higher baseline viral load, measured by both RT-qPCR cycle threshold and log10 copies/mL, was associated with greater supplemental oxygenation requirements and disease severity at study entry. Higher baseline viral load was associated with higher mortality, lower likelihood of improvement in clinical status and supplemental oxygenation requirements, and lower rates of hospital discharge. Viral load was not impacted by sarilumab treatment over time versus placebo.
Conclusions: These data support viral load as an important determinant of clinical outcomes in hospitalized patients with COVID-19 requiring supplemental oxygen or assisted ventilation.
Keywords: COVID-19; hospital; outcomes; severity; viral load.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures
References
- Wölfel R, Corman VM, Guggemos W, et al. . Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581:465–9.
- Zheng S, Fan J, Yu F, et al. . Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 2020; 369:m1443.
- Fajnzylber J, Regan J, Coxen K, et al. ; Massachusetts Consortium for Pathogen Readiness. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun 2020; 11:5493.
- Zacharioudakis IM, Prasad PJ, Zervou FN, et al. . Association of SARS-CoV-2 genomic load with outcomes in patients with COVID-19. Ann Am Thorac Soc 2021; 18:900–3.
- Wang Y, Zhang D, Du G, et al. . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395:1569–78.
- Weinreich DM, Sivapalasingam S, Norton T, et al. ; Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021; 384:238–51.
- Westblade LF, Brar G, Pinheiro LC, et al. . SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell 2020; 38:661–71.e2.
- Magleby R, Westblade LF, Trzebucki A, et al. . Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. Clin Infect Dis 2020:ciaa851. doi: 10.1093/cid/ciaa851.
- Sivapalasingam S, Lederer DJ, Bhore R, et al. . A randomized placebo-controlled trial of sarilumab in hospitalized patients with Covid-19 [preprint ]. medRxiv 2021:2021.05.13.21256973. doi: 10.1101/2021.05.13.21256973.
- Peterson RL, Vock DM, Powers JH, et al. ; INSIGHT FLU-IVIG Study Group. Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. Clin Trials 2017; 14:264–76.
- Argyropoulos KV, Serrano A, Hu J, et al. . Association of initial viral load in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and symptoms. Am J Pathol 2020; 190:1881–7.
Source: PubMed